NCT01837823View on ClinicalTrials.gov

YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Obstructive Coronary Artery DiseaseCoronary Artery Disease
Interventions
DRUG

rosuvastatin

All subjects will receive rosuvastatin 40mg/day for 8-12 weeks

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab)

UNKNOWN

collaborator

AstraZeneca

INDUSTRY

collaborator

InfraReDx (indirect)

UNKNOWN

lead

Icahn School of Medicine at Mount Sinai

OTHER